News - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

News


Pharmaceutical Technology Europe
Volume 23, Issue 12

News bites

EC probes J&J and Novartis

The European Commission has launched another antitrust investigation, this time examining whether contracts between Johnson & Johnson and Novartis were designed to delay the market entry of generic versions of Fentanyl in the Netherlands.

Read more at: http://www.PharmTech.com/ecprobe

GSK's US settlement

GlaxoSmithKline has come to a tentative agreement with the US government to conclude ongoing investigations relating to sales and marketing practices. The settlement is still subject to negotiation, but GSK expects to pay around $3 billion, which is covered by existing legal provisions.

Read more at: http://www.PharmTech.com/gsksettles

Lily–Amyline alliance ends

Eli Lilly and Amylin have terminated their alliance relating to the diabetes medication exenatide. Amylin will have responsibility for exanatide's global development and commercialisation while Eli Lilly will receive an upfront payment of $250 million and a secured note for $1.2 billion plus interest.

Read more at: http://www.PharmTech.com/lillyamylin

Annex 16 revisions

The EMA has released a concept paper for consultation that recommends a revision to Annex 16 of the Guide to Good Manufacturing of Medicinal Products. According to the EMA, the revision will address new falsified medicines legislation and the industry's complicated global supply chains.

Read more at: http://www.PharmTech.com/annex16


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
8%
Protecting the supply chain
40%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology Europe,
Click here